Thanks for your interest in the PERISCOPE newsletter. You may also be interested in these resources:
Periscope Sign up for our business development newsletter
For those who serve bio/pharma, medical device and diagnostic companies.
M&A in the CMC Services Industry: Implications and Outlook
In the three-year period 2014-2016 there were 101 acquisitions of CMC services companies, including dose and API manufacturing, packaging, logistics, formulation and analytical services. Learn how M&A in the bio/pharma contract services industry is likely to play out over the next two years.
How can small/mid-size pharma companies get attention of top CMOs?
A lot depends on who is getting the approvals and the nature of… Jim Miller weighs in
How big is the market for…?
We often are asked the size of the market for various segments of the bio/pharma contract services industry. In response, we’ve developed a resource page that addresses… Learn more.
Follow the Money to Pharmaceutical Opportunities
Spotlight on BioCryst Pharmaceuticals, Inc.
BioCryst plans to raise $45 million in a secondary public offering.
What new business opportunities are most likely to surface from this? We know they plan to use the proceeds for future clinical development of BCX7353, for continued development of its second-generation compounds for HAE and… read on.
Contract Manufacturing Through the Years
The 40 years during which Pharmaceutical Technology has served the bio/pharma industry have been years of momentous growth and change in the way drugs are discovered, developed, manufactured, and sold. CDMOs have long played a part in the industry’s growth, but… See Jim Miller’s Outsourcing Outlook Archive.
“We are nearly fully booked for the next 18+ months, with full credit going to the PharmSource Lead Sheet.”
Read more from other satisfied clients.
Not So NICE:
European Drug Pricing to Impact CMO Profitability and Performance. Learn more about how European drug-rationing policies could affect pharmaceutical manufacturing profitability – and future operations – in the EU, US and elsewhere.
Dose CMOs by the Numbers
The contract dose manufacturing universe includes 282 companies headquartered primarily in North America, Europe, Japan and India. Nearly 64% of those companies pursue contract manufacturing as their primary business, while the others contract manufacture in facilities where they produce their own products. Learn more about the implications for the dose CMO industry.
Galapagos reports positive results from a Phase IIa trial with GLPG1690 for the treatment of idiopathic pulmonary fibrosis. Become a subscriber and have leads like this one delivered weekly.